Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/pbc.32032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience Adam P. Yan Yuqing Feng Dima El Hassanieh Allison Starr Martin Yi Tal Schechter‐Finkelstein Jennifer Drynan Lillian Sung Sumit Gupta Pediatric Blood & Cancer ABSTRACT Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, offers single‐dose seasonal protection. We conducted a single‐center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024–2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non‐recipients, including one RSV‐related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations. 10.1002/pbc.32032 http://onlinelibrary.wiley.com/termsAndConditions#vor